In the press
Pre-clinical Biotech Development Opportunity Video
Pre-clinical Biotech Development Opportunity Video
Related Press
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend
Genexys BioMed Awarded $320K SBIR Grant to Advance Novel Cystic Fibrosis Gene Therapy
NIH Grant to Accelerate Development of Innovative Non-Viral, Non-Lipid Platform Originating from Cincinnati Children’s CINCINNATI, Ohio, July 30, 2024 — Genexys BioMed, a pre-clinical stage biotechnology company developing a novel non-viral, non-lipid genetic medicine platform for the treatment of cystic fibrosis (CF) and other genetic diseases, announced today it has been awarded a $320,000 Phase
The University of Pittsburgh and Orange Grove Bio Establish Partnership …
The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration “Orange Grove Bio, a preclinical drug investment and development firm, and
New Partnership Continues Pitt’s Turn Toward Commercializing Research
New Partnership Continues Pitt’s Turn Toward Commercializing Research The following excerpt was taken from Pittsburgh Post-Gazette — continue reading here. An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies “An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies targeting
Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology
OGB Also Announces Key Appointments to Board of Senior Advisors and the Opening of New Headquarters The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, Sept. 28, 2023 (GLOBE NEWSWIRE) Orange Grove Bio (OGB), a drug investment and development firm, today announced that Preservation Bio, one of the firm’s majority-owned subsidiaries, has been
Orange Grove Bio and University of Chicago Form Strategic Partnership to Accelerate Biotech Innovation and Commercialization
Collaboration Aims to Bridge the Gap Between Academic Research and Commercial Development, Fostering a Thriving Biotech Ecosystem in Chicago CINCINNATI, Ohio, July 23, 2024 — Orange Grove Bio, a leading integrated biopharmaceutical company, and the University of Chicago’s Polsky Center for Entrepreneurship and Innovation today announced a strategic partnership to catalyze the successful commercialization of
Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science
Partnership represents firm’s second international collaboration and provides access to groundbreaking research taking place within world’s fifth largest pharmaceutical market The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, January 31, 2023 (GLOBE NEWSWIRE) – Orange Grove Bio, a drug investment and development firm, today announced that it has established a new
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area The following excerpt was taken from Cincinnati Enquirer — continue reading here. Orange Grove Bio, a venture capital firm that invests mainly in therapeutic drug companies, is moving its headquarters from the New York City “Orange Grove Bio, a venture capital firm that invests
Wall Street Journal
Wall Street Journal The following was taken from the Wall Street Journal. Check out the original piece here: https://www.wsj.com/articles/vc-daily-biotechs-test-new-company-building-model-11614261635 We are incredibly excited and humbled to be recognized in the Wall Street Journal for our innovative business model! We thank everyone who has been supporting us from the beginning.